☆ 4.6 Letter

Lower anti-spike levels in B-cell-depleted patients after convalescent plasma transfusion suggest the need for repeated doses

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.
Article Hematology

Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents

David Gachoud et al.

Summary: This study found that COVID-19 patients who were pre-exposed to anti-CD20 treatments experienced a more rapid decline in anti-spike IgG levels after plasma therapy, along with longer clinical symptoms and higher viral loads. These patients also had higher mutation rates compared to those who were able to mount an endogenous humoral response, potentially indicating immune escape.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection
Review Virology

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

Daniele Focosi et al.

Summary: Evusheld (R) is the first cocktail of anti-Spike monoclonal antibodies designed for both treatment and pre-exposure prophylaxis. It has shown clinical efficacy, but its effectiveness against the Omicron variant is limited.

VIRUSES-BASEL (2022)

Add to Collection
Article Multidisciplinary Sciences

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

David J. Sullivan et al.

Summary: The study suggests that convalescent plasma has a high neutralizing effect against the Omicron variant, while vaccinated individuals also show good neutralizing effects. These findings have implications for both previous CCP stocks and future plans to restart CCP collections.

NATURE COMMUNICATIONS (2022)

Add to Collection
Review Infectious Diseases

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies

Daniele Focosi et al.

Summary: This study focuses on separating study design variables that could affect the clinical outcome of COVID-19 convalescent plasma therapy. Neglecting variables such as pretransfusion antibody testing in recipients, dose adjustments, and antibody affinity measurements has impacted the outcomes of the majority of clinical trials to date. Understanding and addressing these variables is crucial for the design of future CCP clinical trials to improve clinical outcomes and reduce risks of immune evasion.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.